Self-reported Morisky score for identifying nonadherence with cardiovascular medications

被引:154
作者
Shalansky, SJ
Levy, AR
Ignaszewski, AP
机构
[1] St Pauls Hosp, Dept Pharm, Vancouver, BC V6Z 1Y6, Canada
[2] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[3] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada
[4] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada
[5] St Pauls Hosp, Heart Funct Clin, Vancouver, BC V6Z 1Y6, Canada
[6] St Pauls Hosp, Hlth Heart Clin, Vancouver, BC V6Z 1Y6, Canada
关键词
adherence; cardiovascular medications;
D O I
10.1345/aph.1E071
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: The Morisky medication adherence scale is a commonly used adherence screening tool. It is composed of 4 yes/no questions about past medication use patterns and is thus quick and simple to use during drug history interviews. OBJECTIVE: To evaluate the use of the self-reported Morisky score as a screening tool for identifying patients who have been nonadherent with chronic cardiovascular medications. METHODS: Patients who had taken an angiotensin-converting enzyme inhibitor or lipid-lowering agent for at least 3 consecutive months were interviewed using a structured questionnaire including the Morisky scale. Nonadherence was defined as taking <80% of chronic cardiovascular medications based on prescription refill data over the previous 14 months. RESULTS: Forty-nine of 377 (13%) patients were categorized as nonadherent; however, only 12 (3%) patients had Morisky scores suggesting a high likelihood of nonadherence (3 or 4). While the Morisky score was a significant independent predictor of nonadherence by multivariate analysis, there was no threshold score or individual question that yielded concurrent high sensitivity and positive predictive values (PPVs) for identifying nonadherent patients. The internal consistency of the questions was low (alpha 0.32), as were item-to-total score correlations, suggesting that the individual questions were not measuring the same attribute. CONCLUSIONS: Using the Morisky scale to identify patients who have been nonadherent with chronic cardiovascular medications may be reasonable in some settings; however, the threshold score would have to be chosen based on a trade-off between sensitivity and PPV. These results were likely influenced by the low rate of nonadherence in this cohort. Rewording the questions, increasing the number of questions, and the use of graded response options may improve consistency.
引用
收藏
页码:1363 / 1368
页数:6
相关论文
共 21 条
[1]  
ANDERSON GM, 1993, INQUIRY-J HEALTH CAR, V30, P199
[2]   DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS [J].
ANDRADE, SE ;
WALKER, AM ;
GOTTLIEB, LK ;
HOLLENBERG, NK ;
TESTA, MA ;
SAPERIA, GM ;
PLATT, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1125-1131
[3]   Long-term persistence in use of statin therapy in elderly patients [J].
Benner, JS ;
Glynn, RJ ;
Mogun, H ;
Neumann, PJ ;
Weinstein, MC ;
Avorn, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (04) :455-461
[4]  
*BRIT COL MIN HLTH, PHARMNET
[5]   Assessing compliance to antihypertensive medications using computer-based pharmacy records [J].
Christensen, DB ;
Williams, B ;
Goldberg, HI ;
Martin, DP ;
Engelberg, R ;
LoGerfo, JP .
MEDICAL CARE, 1997, 35 (11) :1164-1170
[6]   WHAT IS COEFFICIENT ALPHA - AN EXAMINATION OF THEORY AND APPLICATIONS [J].
CORTINA, JM .
JOURNAL OF APPLIED PSYCHOLOGY, 1993, 78 (01) :98-104
[7]   Compliance from self-reported versus pharmacy claims data with metered-dose inhalers [J].
Erickson, SR ;
Coombs, JH ;
Kirking, DM ;
Azimi, AR .
ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) :997-1003
[8]  
Gao X, 2000, ANN PHARMACOTHER, V34, P1117
[9]   Compliance with tricyclic antidepressants: the value of four different methods of assessment [J].
George, CF ;
Peveler, RC ;
Heiliger, S ;
Thompson, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (02) :166-171
[10]   The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: Results of the First Myocardial Infarction Risk Reduction Program [J].
Guthrie, RM .
CLINICAL THERAPEUTICS, 2001, 23 (06) :970-980